Halozyme Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $63.0M | $-103.0M | $-32.2M | $-68.4M | $-83.5M | $-53.6M | $-19.8M | $-53.2M |
| Depreciation & Amortization | $2.2M | $2.4M | $1.7M | $1.8M | $1.2M | $1.1M | $1.1M | $1.5M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $30.7M | $25.6M | $20.8M | $15.3M | $9.5M | $8.3M | $5.6M | $4.9M |
| Net Cash from Operating Activities | $134.1M | $-50.4M | $-37.1M | $-47.5M | $-49.3M | $-64.3M | $-34.3M | $-45.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.4M | $3.1M | $2.4M | $1.4M | $2.3M | $1.4M | $828.5K | $646.5K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-163.7M | $-76.8M | $5.9M | $-33.0M | $-47.9M | $-1.4M | $-828.5K | $-646.5K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $0 | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $131.7M | $150.6M | $13.1M | $114.5M | $25.1M | $112.8M | $4.7M | $61.8M |
| Net Change in Cash | $102.0M | $23.5M | $-18.1M | $34.0M | $-72.1M | $47.1M | $-30.4M | $15.8M |
| Free Cash Flow | $132.7M | $-53.5M | $-39.4M | $-48.9M | $-51.6M | $-65.7M | $-35.1M | $-46.0M |